Pembrolizumab-induced Stevens–Johnson syndrome in non-melanoma patients

European Journal of Cancer

Volumn 81, Issue , 2017, Pages 237-239

  Saw, Stephanie ^a   Lee, Haur Yueh ^b   Ng, Quan Sing ^a  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; DEXAMETHASONE; LEVOFLOXACIN; PEMBROLIZUMAB; PREDNISOLONE; MONOCLONAL ANTIBODY;

ADULT; BLISTER; BODY SURFACE; BONE METASTASIS; CANCER PATIENT; CANCER RADIOTHERAPY; CASE REPORT; CHEILITIS; CONJUNCTIVITIS; DERMATITIS; DRUG DOSE INCREASE; EOSINOPHIL; EPIDERMOLYSIS; EPITHELIZATION; FEMALE; HUMAN; INFLAMMATORY INFILTRATE; KIDNEY CARCINOMA; LETTER; LYMPHOCYTE; MALE; METASTASIS; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CARCINOMA; NECROSIS; ORAL MUCOSITIS; PAPULE; PRIORITY JOURNAL; RASH; SARCOMATOID CARCINOMA; SKIN BIOPSY; STEVENS JOHNSON SYNDROME; TREATMENT DURATION; TREATMENT RESPONSE; CARCINOMA; KIDNEY TUMOR; NASOPHARYNX TUMOR; PATHOLOGY; RENAL CELL CARCINOMA;

ANTIBODIES, MONOCLONAL, HUMANIZED; CARCINOMA; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; STEVENS-JOHNSON SYNDROME;

EID: 85018660637     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2017.03.026     Document Type: Letter

References (9)

1. Nayar, N., Briscoe, K., Fernandez Penas, P., Toxic epidermal necrolysis-like reaction with severe satellite cell necrosis associated with nivolumab in a patient with ipilimumab refractory metastatic melanoma. J Immunother 39:3 (2016 Apr), 149–152.
2. Vivar, K.L., Deschaine, M., Messina, J., Divine, J.M., Rabionet, A., Patel, N., et al. Epidermal anti-programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy. J Cutan Pathol 44:4 (2017 Apr), 381–384.
3. Liniker, E., Menzies, A.M., Kong, B.Y., Cooper, A., Ramanujam, S., Lo, S., et al. Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma. Oncoimmunology, 5(9), 2016 Aug 19, e1214788.
4. Goldinger, S., Stieger, P., Meier, B., Micaletto, S., Contassot, E., French, L., et al. Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy. Clin Cancer Res 22:16 (15 August 2016), 4023–4029.
5. Hwang, S.J., Carlos, G., Wakade, D., Byth, K., Kong, B.Y., Chou, S., et al. Cutaneous adverse events of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort. J Am Acad Dermatol 74 (2016), 455–461.
6. Habre, M., Habre, S.B., Kourie, H.R., Dermatologic adverse events of checkpoint inhibitors: what an oncologist should know. Immunotherapy 8:12 (2016 Dec), 1437–1446.
7. Kroeze, S.G., Fritz, C., Hoyer, M., Lo, S.S., Ricardi, U., Sahgal, A., et al. Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy. Cancer Treat Rev 53 (2016), 25–37.
8. Vern-Gross, T.Z., Kowal-Vern, A., Erythema multiforme, Stevens–Johnson syndrome and toxic epidermal necrolysis in patients undergoing radiation therapy: a literature review. Am J Clin Oncol 37 (2014), 506–513.
9. Lee, H.Y., Fook-Chong, S., Koh, H.Y., Thirumoorthy, T., Pang, S.M., Cyclosporine treatment for Stevens-Johnson syndrome/toxic epidermal necrolysis: retrospective analysis of a cohort treated in a specialized referral center. J Am Acad Dermatol 76 (2017), 106–113.